febit First to Offer miRBase 11.0 Biochip

MEDFORD, Mass. and HEIDELBERG, Germany, April 14 /PRNewswire/ -- febit today announced its newest miRNA Biochip based on the new miRBASE version 11.0 which has been released by the Wellcome Trust Sanger Institute yesterday. The new Geniom(R) Biochip opens up the most up-to-date scientific information for miRNA microarray experiments.

febit's flexible Geniom Platform and Services give researchers in the field of genomics access to the latest version of miRBase. The Geniom Biochip can be used as a full service from febit or as a ready-to-go biochip for the new microarray analyzing device from febit, the Geniom RT Analyzer. The Geniom RT Analyzer recently launched in Europe and will be launched in the United States at the RNAi World Congress in Boston (May 1-2, 2008).

About febit

febit enables scientists to read, write and understand the code of life: DNA. With its unique Geniom technology and services, febit is the only company that puts the control of simplified genomic research in the hand of the user. The seamless integration of DNA synthesis and analysis and the superior support in experiment design and bioinformatics helps to understand data and turn it into results. febit's team of experienced scientists is dedicated to support customers to solve the challenge of understanding biological processes. Geniom is a technological and service platform successfully implemented in basic and applied research by renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes, providing superior time- and cost-efficiency combined with an unsurpassed spectrum of applications.

SOURCE febit

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.